Therefore, combining PCSK9 inhibitors with ICIs may not only reduce the risk of ASCVD but also improve the efficacy of antitumor therapy, particularly in patients who exhibit poor response due to reduced MHC-I expression [87]. Here, PCSK9 is linked to atherosclerosis.